Value of oxidant lipid lowering effect by statin intervension in hypercholesterolemia.
- Conditions
- Hypercholesterolemia
- Registration Number
- JPRN-UMIN000001783
- Lead Sponsor
- Jikei University Kashiwa Hospital
- Brief Summary
The VISION study describes the first comparison on lipoprotein oxidation biomarkers between pitavastatin and atorvastatin and suggests diverse effects on lipoprotein oxidation markers in patients with hypercholesterolemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
(1)Hypersensitivity for statin treatment. (2)Hepatic disorder (AST or ALT >=100 IU/L), biliary atresia, or suspected hepatic metabolism disorders (acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer, and jaundice). (3)Renal disorder (serum creatinine >= 1.5mg/dL). (4)Receiving cyclosporine. (5)Receiving probucol. (6)Receiving tocopherol. (7)Receiving hormone replacement therapy. (8)Uncontrolled hypothyroidism. (9)Pregnant women, women who may be pregnant, and breast-feeding women. (10)Patients who were judged unsuitable by their doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1)Change and percent change in oxidized Lp(a) lipoprotein. (2)Change and percent change in oxidized LDL.
- Secondary Outcome Measures
Name Time Method (1)Change and percent change in TC, LDL-C, TG and HDL-C. (2)Change and percent change in apo A-1 and apo B. (3)Change and percent change in Lp(a) protein and RLP-C. (4)Change and percent change in Mg. (5)Change of various serum lipoprotein cholesterol by HPLC. (6)Change and percent change in vitamin E. (7)Change and percent change in MDA-LDL. (8)Change and percent change in adiponectin. (9)Change and percent change in small dense LDL. (10)Change and percent change in oxidized HDL.